171 related articles for article (PubMed ID: 34664788)
1. Safety of thoracic radiotherapy after PD-(L)1 inhibitor treatment in patients with lung cancer.
Chen Y; Liu X; Huang Z; Zhao K; Wang Y; Ren F; Yu J; Meng X
Cancer Med; 2021 Dec; 10(23):8518-8529. PubMed ID: 34664788
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer.
Lu X; Wang J; Zhang T; Zhou Z; Deng L; Wang X; Wang W; Liu W; Tang W; Wang Z; Wang J; Jiang W; Bi N; Wang L
Front Immunol; 2022; 13():918787. PubMed ID: 35795657
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy.
Saito S; Abe T; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Yamaguchi O; Kaira K; Kagamu H; Noda SE; Kato S
J Radiat Res; 2021 Jul; 62(4):669-675. PubMed ID: 34121123
[TBL] [Abstract][Full Text] [Related]
4. The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy.
Chen F; Niu J; Wang M; Zhu H; Guo Z
Radiat Oncol; 2024 May; 19(1):67. PubMed ID: 38816745
[TBL] [Abstract][Full Text] [Related]
5. Toxicity profile of combined immune checkpoint inhibitors and thoracic radiotherapy in esophageal cancer: A meta-analysis and systematic review.
Xu T; Liu Y; Lu X; Liang J
Front Immunol; 2022; 13():1039020. PubMed ID: 36439117
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer.
Peng J; Zhang L; Wang L; Feng H; Yao D; Meng R; Liu X; Li X; Liu N; Tan B; Huang Z; Li S; Meng X
Radiat Oncol; 2023 Jul; 18(1):111. PubMed ID: 37403111
[TBL] [Abstract][Full Text] [Related]
7. Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review.
Li B; Jiang C; Pang L; Zou B; Ding M; Sun X; Yu J; Wang L
Front Immunol; 2021; 12():627197. PubMed ID: 33859637
[TBL] [Abstract][Full Text] [Related]
8. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.
Voong KR; Hazell SZ; Fu W; Hu C; Lin CT; Ding K; Suresh K; Hayman J; Hales RK; Alfaifi S; Marrone KA; Levy B; Hann CL; Ettinger DS; Feliciano JL; Peterson V; Kelly RJ; Brahmer JR; Forde PM; Naidoo J
Clin Lung Cancer; 2019 Jul; 20(4):e470-e479. PubMed ID: 31031204
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.
Fujimoto D; Miura S; Yoshimura K; Wakuda K; Oya Y; Yokoyama T; Yokoi T; Asao T; Tamiya M; Nakamura A; Yoshioka H; Haratani K; Teraoka S; Tokito T; Murakami S; Tamiya A; Itoh S; Yokouchi H; Watanabe S; Yamaguchi O; Tomii K; Yamamoto N
Eur J Cancer; 2021 Jun; 150():63-72. PubMed ID: 33892408
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
[TBL] [Abstract][Full Text] [Related]
11. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.
Yamaguchi T; Shimizu J; Hasegawa T; Horio Y; Inaba Y; Yatabe Y; Hida T
Lung Cancer; 2018 Nov; 125():212-217. PubMed ID: 30429022
[TBL] [Abstract][Full Text] [Related]
12. Organizing pneumonia after thoracic radiotherapy followed by anti-PD-1 antibody treatment for patients with lung cancer: Three case reports.
Sakaguchi M; Maebayashi T; Aizawa T; Ishibashi N; Okada M
Thorac Cancer; 2019 Jun; 10(6):1503-1507. PubMed ID: 31124295
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors.
Bi J; Qian J; Yang D; Sun L; Lin S; Li Y; Xue X; Nie T; Verma V; Han G
Front Immunol; 2021; 12():828858. PubMed ID: 35095930
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of extensive stage small cell lung carcinoma patients treated with consolidative thoracic radiotherapy.
Giuliani ME; Atallah S; Sun A; Bezjak A; Le LW; Brade A; Cho J; Leighl NB; Shepherd FA; Hope AJ
Clin Lung Cancer; 2011 Nov; 12(6):375-9. PubMed ID: 21729647
[TBL] [Abstract][Full Text] [Related]
15. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer.
Cousin F; Desir C; Ben Mustapha S; Mievis C; Coucke P; Hustinx R
Radiother Oncol; 2021 Apr; 157():47-55. PubMed ID: 33453313
[TBL] [Abstract][Full Text] [Related]
16. Decreased metastasis and improved survival with early thoracic radiotherapy and prophylactic cranial irradiation in combined-modality treatment of limited-stage small cell lung cancer.
Kamath SS; McCarley DL; Zlotecki RA
Radiat Oncol Investig; 1998; 6(5):226-32. PubMed ID: 9822169
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
18. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
20. Early administration of durvalumab after chemoradiotherapy increased risk of pneumonitis in patients with locally advanced non-small cell lung cancer.
Harada D; Shimonishi A; Saeki K; Ninomiya T; Kanzaki H; Nagasaki K; Ogura C; Tsutsui Y; Kojin K; Hamamoto Y; Kozuki T
Asia Pac J Clin Oncol; 2023 Apr; 19(2):e111-e117. PubMed ID: 35686586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
